Calcilytix Therapeutics, Inc., A Bridgebio Company

This study tests a drug called encaleret in children (birth to 17 years) with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic condition causing low blood calcium and high urine calcium. The goal is to see if the drug can safely normalize calcium levels. About 28 par…